The stock was sold as the share price reached the revised target price.
Daiichi Sankyo ranks as the second largest pharmaceutical company, having been formed through the merger of Sankyo and Daiichi Pharmaceutical in April 2007. The worst of a double-hit from the expiration of the US patent for their anti-hyperlipidemic drug, Mevalotin, and one-offs from the consolidation, have now peaked out. The good news is that their anti-hypertensive drug, Olmetech, is growing faster than expected, having started selling in the US back in October. The company is also strong in the cardiovascular area, which provides good potential with drugs at various trial stages.